Clinical Trial Detail

NCT ID NCT03563170
Title QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors NantKwest, Inc.
Indications

hepatocellular carcinoma

Therapies

Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Sorafenib

Sorafenib

Age Groups: adult senior

No variant requirements are available.